Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Table 2 Summary of anti-sCTLA-4 mAb blockade effect on healthy donor and SLE patient peripheral blood mononuclear cell responses to control antigens and three stimulatory peptide autoantigens (H3_91-105, H4_71-93, and U170K_131-151)

Peptide	Dose	Proliferation		IFN-γ		IL-17		IL-10
	(μg/ml)	Healthy	SLE	Healthy	SLE	Healthy	SLE	Healthy	SLE
Resting^†	-	ns	***⇩	ns	ns	ns	ns	ns	***⇧
U170K	10	*⇩	**⇩	ns	ns	ns	*⇩	ns	**⇧
	20	*⇩	*⇩	ns	ns	ns	**⇩	ns	ns
H3	10	ns	ns	ns	ns	ns	*⇩	ns	ns
	20	ns	**⇧	ns	ns	ns	ns	*⇩	*⇩
H4	10	**⇩	ns	ns	ns	*⇩	ns	*⇩	***⇧
	20	ns	ns	ns	ns	ns	ns	ns	***⇧
PPD	5	**⇧	ns	***⇧	ns	ns	ns	ns	*⇧
αCD3	5	ns	*⇩	ns	**⇩	ns	*⇩	ns	ns

*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
CD cluster of differentiation, H3, histone 3, H4 histone 4, IFN interferon, IL interleukin, ns not significant, PPD purified protein derivative, SLE systemic lupus erythematosus, U170K U1 small nuclear ribonucleoprotein 70 kDa
† = resting PBMC at day 5. Arrows next to probabilty asterix represent significant increase or decrease in test sample

ISSN: 1478-6362